{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-24-008002","form_type":"8-K","ticker":null,"cik":"0000887247","company_name":"DMK PHARMACEUTICALS Corp","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.182049+00:00","generated_at":"2026-06-01T00:21:47.881355+00:00","sec_items":["2.01","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DMK Pharmaceuticals sells ZIMHI assets for $3.17M; entire board and CEO resign effective June 27, 2024","bullets":["Sold ZIMHI assets to zmi pharma inc. for $3,170,600 on May 16, 2024, approved by Bankruptcy Court.","Chairman and CEO Ebrahim Versi resigned as director and CEO effective June 27, 2024.","All other directors (Birndorf, Desai, Reed, J. Versi) resigned; no disagreements cited.","General Counsel John Dorbin separated; CFO Seth Cohen named Chief Restructuring Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-24-008002","json":"https://secwatch.observer/filing/0001999371-24-008002.json","markdown":"https://secwatch.observer/filing/0001999371-24-008002.md","text":"https://secwatch.observer/filing/0001999371-24-008002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/dmk-8k_051624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:21:47.881355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6dba4c11f3","claim":"Vickie S. Reed resigned as Director at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"79a900fa56","claim":"Jannine C. A. Versi resigned as Director at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a27a1db149","claim":"Meera J. Desai resigned as Director at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a5cbf3609f","claim":"Seth Cohen changed role as Chief Restructuring Officer at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Effective June 27, 2024, Seth Cohen, the Company’s Chief Financial officer will assume the role of Chief Restructuring Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed the role of"},{"label":"Role","value":"Chief Restructuring Officer"}],"fact_type":"executive_change"},{"claim_id":"b4d4471cc9","claim":"Ebrahim “Eboo” Versi resigned as Chairman of the Board at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Effective June 27, 2024, Ebrahim “Eboo” Versi, M.D., Ph.D. resigned as Chairman of the Board and as a Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"d37657a1ca","claim":"John W. Dorbin, Jr. departed as General Counsel and Corporate Secretary at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"John W. Dorbin, Jr. was also separated from his role as General Counsel and Corporate Secretary of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"General Counsel and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"ee6e35126a","claim":"Howard C. Birndorf resigned as Director at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f71a77fcbf","claim":"Ebrahim “Eboo” Versi departed as Chief Executive Officer at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Also effective June 27, 2024, Mr. Versi was separated from his role as Chief Executive Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9dd244d40dfc37f923bd419e847d9d7982831fff","claim":"DMK PHARMACEUTICALS Corp completed a disposition involving zmi pharma inc. for $3,170,600 (closed 2024-05-16).","evidence_excerpt":"On May 16, 2024, pursuant to an agreement approved by the Bankruptcy Court, the Company sold all of its assets relating to its ZIMHI products and business to zmi pharma inc. for $3,170,600.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000199937124008002/0001999371-24-008002-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"zmi pharma inc."},{"label":"Consideration","value":"$3,170,600"},{"label":"Closing","value":"2024-05-16"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}